Johnson & Johnson Q3 2024 Earnings Conference Call
October 15, 2024 8:30 AM ET
Welcome to Johnson & Johnson’s Third Quarter 2024 Earnings Conference Call. Today, we will be discussing the financial performance of the company with key executives providing insights on our results. Let’s delve into the highlights of the call.
Company Participants:
Jessica Moore – Vice President, Investor Relations
Joaquin Duato – Chairman & Chief Executive Officer
Joe Wolk – Executive Vice President, Chief Financial Officer
Erik Haas – Head, Worldwide Litigation
Tim Schmid – Executive Vice President, Worldwide Chairman, MedTech
Jennifer Taubert – Executive Vice President, Worldwide Chairman, Innovative Medicine
John Reed – Executive Vice President, Innovative Medicine, R&D
Conference Call Participants:
Chris Schott – JPMorgan
Larry Biegelsen – Wells Fargo
Louise Chen – Cantor Fitzgerald
Terence Flynn – Morgan Stanley
Danielle Antalffy – UBS
Shagun Singh – RBC Capital Markets
Vamil Divan – Guggenheim Securities
Jayson Bedford – Raymond James
The conference call began with an introduction by the operator, informing all participants that they would be in a listen-only mode until the question-and-answer session later in the call.
Impact on Individuals
As an individual, the insights shared in Johnson & Johnson’s earnings conference call can provide valuable information for investors and stakeholders. Understanding the company’s financial performance can help individuals make informed decisions regarding their investments in the company’s stock or products. It also gives a glimpse into the overall health and strategy of the organization, which can be crucial for individuals looking to engage with the company in any capacity.
Impact on the World
Johnson & Johnson is a globally recognized healthcare company, and its financial performance has far-reaching implications for the world. The company’s innovative medicines, medical devices, and consumer health products play a significant role in improving healthcare outcomes worldwide. A strong financial performance by Johnson & Johnson can translate to continued innovation, research and development, and philanthropic initiatives that benefit communities around the globe.
Conclusion
In conclusion, Johnson & Johnson’s Third Quarter 2024 Earnings Conference Call provided key insights into the company’s financial performance and future outlook. The participation of top executives and analysts highlighted the strategic direction of the company and its commitment to driving growth and innovation in the healthcare industry. As individuals and global citizens, we look forward to the continued impact of Johnson & Johnson’s initiatives on our lives and the world at large.
